ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION FOR STANDARD-RISK LEUKEMIA - A MULTICENTER PILOT-STUDY - JAPANESE EXPERIENCE

A multicenter phase II study of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) was conducted. Twenty-two patients (media n age, 36 years) with standard-risk leukemia were transplanted with CS F-mobilized PBSC from an HLA-identical sibling donor, and received cyc losporine and methotrexate for GVHD prevention, Median days to ANC >50 0/mu l and platelets >50 000/mu l were 12 (9-20) and 16 (11-32), respe ctively. Grade II-IFT acute GVHD developed in 6/21 (29%) and extensive chronic GVHD in 12/20 (60%). These observations indicate that allo-PB SCT is characterized by rapid hematologic engraftment, no increase of acute GVHD and an increased risk of chronic GVHD, and can be used as a n alternative to allogeneic hone marrow transplantation.